In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole

Hiroyuki Sasabe,Toshihisa Koga,Masayuki Furukawa,Masayuki Matsunaga,Katsunori Sasahara,Kenta Hashizume,Yoshihiro Oozone,Immaculate Amunom,Mikako Torii,Ken Umehara,Eiji Kashiyama,Kenji Takeuchi

In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole

2021

Hiroyuki Sasabe
Toshihisa Koga
Masayuki Furukawa
Masayuki Matsunaga
Katsunori Sasahara
Kenta Hashizume
Yoshihiro Oozone
Immaculate Amunom
Mikako Torii
Ken Umehara
Eiji Kashiyama
Kenji Takeuchi

Brexpiprazole, a serotonin-dopamine activity modulator, is indicated for the treatment of schizophrenia and also adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder...

Keywords:

Dopamine
Schizophrenia
Pharmacology
Drug
ATP-binding cassette transporter
Serotonin
Brexpiprazole
Medicine
Major depressive disorder
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations